Please select a Capability in order to start your service request.
Soré Néimatou, 20, has a boyfriend, and is visiting a family planning clinic in the Burkina Faso capital of Ouagadougou."I don't want to get pregnant," she says. "I want to get married first." Today, women in this West African nation have access to an additional family planning option1.
Pfizer’s Sayana® Press has the potential to increase access to contraception at all levels of the health system and in communities by combining a lower-dose formulation of a widely used contraceptive - Pfizer’s Depo-Provera® (medroxyprogesterone acetate oral suspension) - with the BD Uniject™ injection system, originally developed by PATH. Burkina Faso, along with Niger, Senegal and Uganda, were the first countries in the pilot program to introduce Sayana® Press in 2014 and early 2015.
“Family planning is vital if girls and women are to have voice, choice, and control in their lives,” said UK International Development Minister Lynne Featherstone. “Sayana® Press will help expand the contraceptive options available in developing countries, giving more girls and women the chance to make their own decisions about whether and when to have children.”
The local pilot program introductions are being led by the ministries of health from the four inaugural countries and supported by a consortium of public and private partners that includes the Bill & Melinda Gates Foundation, the Children’s Investment Fund Foundation (CIFF), the UK’s Department for International Development (DFID), PATH, Pfizer, the United Nations Population Fund (UNFPA) and the US Agency for International Development (USAID).
More recently, a new agreement was announced between the Bill & Melinda Gates Foundation, CIFF and Pfizer, further expanding access to Sayana® Press for women most in need in 69 of the world’s poorest countries.
“Strong public-private partnerships are playing a critical role in expanding contraceptive access and options for women around the world,” said Chris Elias, President of Global Development at the Bill & Melinda Gates Foundation. “This innovative initiative brings us one step closer to ensuring that family planning is available to women when and where they want it.”
Family planning could prevent up to one-third of all maternal deaths by allowing women to delay motherhood, space births, avoid unintended pregnancies and unsafe abortions, and stop childbearing when they reach their desired family size.
“This initiative is a major innovation in family planning service delivery,” said PATH President and CEO Steve Davis. “By making injectable contraceptives available at the community level, it offers more women control over the timing and spacing of their children and a better chance at a healthy life.”